Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Drug-Induced Pulmonary Toxicity Workup

  • Author: Ryland P Byrd, Jr, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
 
Updated: Dec 31, 2015
 

Approach Considerations

The diagnosis of drug-mediated pulmonary toxicity is usually made based on clinical findings. In general, laboratory analyses do not help in establishing the diagnosis.

The complete blood cell count (CBC) may show increased eosinophils in cases of drug-induced pulmonary eosinophilia. However, the absence of peripheral eosinophilia does not exclude a diagnosis of drug-induced eosinophilic pneumonia.

Patients with drug-induced lupus can test positive for antinuclear antibody and positive for antihistone antibody. Anti–double-stranded DNA test results are negative and complement values are normal.

The clinical and radiological manifestations of pulmonary drug toxicity generally reflect the underlying histopathologic processes. High-resolution computed tomography (CT) scanning is more sensitive than chest radiography for defining the radiographic abnormalities.[2]

Other studies that may be indicated include the following:

  • Pulmonary function tests (PFTs)
  • Arterial blood gas (ABG) analyses
  • Flexible bronchoscopy
  • Open lung biopsy or video-assisted thoracoscopic lung biopsy
  • Bronchoalveolar lavage (BAL)
Next

Chest Radiography and Computed Tomography

The radiologic patterns seen in pulmonary drug toxicity can be divided into the following categories:

  • Diffuse alveolar damage (DAD)
  • Interstitial pneumonitis
  • Cryptogenic organizing pneumonia (COP)
  • Pulmonary edema
  • Eosinophilic pneumonia
  • Pulmonary hemorrhage
  • Granulomatous pneumonitis

Diffuse alveolar damage

Drugs implicated in DAD include amiodarone, cyclophosphamide, bleomycin, carbamazepine, etoposide, cocaine, heroin, MTX, and mitomycin C. Depending on the patient and the time of diagnosis, this condition may be difficult to distinguish clinically from pulmonary edema, diffuse alveolar hemorrhage, accelerated pulmonary fibrosis, or dense interstitial pneumonias.

Chest radiographs show bilateral heterogeneous or homogeneous parenchymal consolidation, usually most marked in the dependent lung regions. Fibrosis typically develops within 1 week but, initially, may not be evident on chest radiographs.

High-resolution CT scans in patients with early DAD typically show scattered or diffuse areas of ground-glass opacity and intralobular septal thickening. Kerley lines (interlobular septal thickening) are typically absent.

Interstitial pneumonitis

Both usual interstitial pneumonia and nonspecific interstitial pneumonia (NSIP) have been associated with drug injury. The clinical radiographic manifestations are often identical to those of idiopathic pulmonary fibrosis. NSIP occurs most commonly as a manifestation of amiodarone, MTX, or carmustine toxicity. Gold salts and chlorambucil toxicity are less common causes of NSIP.

Radiographic studies indicate bilateral, usually symmetrical, interstitial or alveolar opacities. The infiltrates may localize in the lung bases or midlung zones or may be diffuse. The radiographic density can be discrete haze, ground-glass, or dense bilateral consolidation with air bronchograms and volume loss.

Early high-resolution CT scans may show only scattered or diffuse areas of ground-glass opacity. Later, findings of fibrosis (traction bronchiectasis, honeycombing) predominate in a basal distribution.

COP

In COP, chest radiographs demonstrate bilateral scattered heterogeneous and homogeneous opacities. These areas are typically located in the periphery and are equally distributed between the upper and lower lobes.

Drugs that can cause COP include acebutolol, amiodarone, amphotericin B, bleomycin, and carbamazepine. Nodular organizing pneumonia, which is typically seen in patients exposed to bleomycin, can be seen as round foci that localize mainly in lung bases; however, they may abut the pleura and simulate metastatic nodules.

CT scanning in COP often shows associated poorly defined nodular areas of consolidation, centrilobular nodules, branching linear opacities, and bronchial dilatation. See the image below.

Standard nonenhanced axial thoracic CT scan shows Standard nonenhanced axial thoracic CT scan shows left lower lobe consolidation with some loss of volume and an air bronchogram. Transbronchial lung biopsy confirmed the diagnosis of cryptogenic organizing pneumonia.

Pulmonary edema

On chest radiographs, typical findings of pulmonary edema include Kerley lines and pleural effusion. Chest CT scanning may show pleural effusion or ground-glass opacity and, to a lesser extent, consolidation.

Eosinophilic pneumonia

Drug toxicity is an important cause of acute and chronic eosinophilic pneumonias. Causative drugs include penicillamine, sulfasalazine, nitrofurantoin, para-aminosalicylic acid, and NSAIDs. Patients also may have blood eosinophilia.

Eosinophilic pneumonia is characterized by the accumulation of eosinophils and macrophages in the alveoli. Imaging studies show pulmonary infiltrates that are typically alveolar and symmetrical and occasionally display the classic pattern of a "photographic negative" of pulmonary edema. However, in drug-induced eosinophilic pneumonia, a reverse pulmonary edema pattern is uncommon. CT scanning can be useful for demonstrating the peripheral nature of the pulmonary opacities.

Pulmonary hemorrhage

Drug-related diffuse pulmonary hemorrhage is uncommon. Typical agents that can cause diffuse pulmonary hemorrhage include anticoagulants, amiodarone, high-dose cyclophosphamide, mitomycin C, cytarabine, and penicillamine. Penicillamine can cause a pulmonary-renal syndrome similar to Goodpasture syndrome.

Chest radiographs typically reveal bilateral heterogeneous and homogenous opacities. High-resolution CT scanning usually shows bilateral, scattered, or diffuse areas of ground-glass opacity. Pleural effusion is typically absent.

Granulomatous pneumonitis

On CT scanning, granulomatous pneumonitis manifests as reticulonodular pulmonary shadows, mediastinal lymph node enlargement, or both, with or without involvement of extrathoracic organs. See the image below. Granulomatosis has been reported in a few patients after treatment of non-Hodgkin lymphoma with chemotherapeutic agents, as well as with cocaine, cromolyn sodium, fluoxetine, methotrexate, nitrofurantoin, procarbazine, and pentazocine.

CT scan of a patient with sarcoidosis illustrating CT scan of a patient with sarcoidosis illustrating multiple nodules. This pattern can manifest in patients taking medications that can cause granulomatous reactions.
Previous
Next

Pulmonary Function Tests and Arterial Blood Gas Analysis

PFTs include spirometry, lung volume determinations, and diffusing capacity of the lungs for carbon monoxide (DLCO). Most drugs cause a restrictive lung disease pattern with decreases in the following:

  • Total lung capacity (TLC)
  • Residual volume (RV)
  • Functional residual capacity (FVC)
  • DLCO

The ratio of forced expiratory volume in 1 second (FEV1) to FVC (FEV1/FVC ratio) may be normal or increased. However, drugs that cause bronchiolitis obliterans or bronchospasm may cause an obstructive ventilatory defect (reduced FEV1/FVC ratio and FEV1, increased RV and RV/TLC ratio).

ABGs may reveal hypoxemia at rest. Arterial oxygen desaturation may occur with exercise. A 6-minute walk test with oximetry provides a measure of oxygen desaturation with exertion and helps detect disease progression.

A baseline PFT and ABG analysis may be useful in individual patients before initiating therapy with a drug known to cause pulmonary toxicity, particularly in cancer patients. DLCO is the most sensitive test to monitor. Some clinicians recommend discontinuing chemotherapy once the DLCO has decreased to greater than or equal to 50% compared with pretherapy values.

Previous
Next

Bronchoalveolar Lavage

BAL findings are not specific for any drug-induced lung disease, and a definitive diagnosis cannot be made based solely on BAL findings. BAL can, however, contribute to the expected clinicopathologic pattern of a given drug-induced lung disease. BAL also is helpful in the differential diagnosis, primarily in excluding an infective cause or involvement of the lungs by the underlying disease (eg, metastatic cancer, malignant lymphoma).

Appropriate stains, cultures, and molecular techniques for BAL fluid should be performed to exclude opportunistic infections. A low ratio of CD4+ to CD8+ lymphocytes is suggestive of, but not specific for, drug-induced lung disease. BAL can be very helpful in the diagnosis of alveolar hemorrhage, for which the BAL fluid shows increased blood staining in sequential aliquots. High eosinophil counts (>40%) in BAL fluid can be seen in patients with drug-induced pulmonary eosinophilia.

BAL findings in amiodarone toxicity are as follows:

  • Positive for neutrophils and "foamy" macrophages
  • Possibly positive for lymphocytes
  • Negative for eosinophils and birefringent particles
  • BAL findings in methotrexate toxicity are as follows:
  • Positive for lymphocytes
  • Negative for neutrophils, macrophages, eosinophils, and birefringent particles
  • BAL findings in bleomycin toxicity are as follows:
  • Positive for neutrophils
  • Possibly positive for lymphocytes and eosinophils
  • Negative for macrophages and birefringent particles
  • BAL findings in talc toxicity are as follows:
  • Positive for birefringent particles
  • Negative for neutrophils, macrophages, lymphocytes, and eosinophils
Previous
Next

Histologic Findings

Histologic changes for most drug reactions are nonspecific, and the diagnosis rests on correlating clinical, laboratory, and radiologic information. The important histopathologic manifestations of pulmonary drug toxicity include the following:

  • DAD
  • NSIP
  • COP
  • Eosinophilic pneumonia
  • Obliterative bronchiolitis
  • Pulmonary hemorrhage
  • Pulmonary vasculitis
  • Granulomatous pneumonitis

DAD

DAD results from necrosis of type 2 pneumocytes and alveolar endothelial cells. The main histopathologic features are as follows[59] :

  • Hyaline membrane formation and fibrin deposits lining the alveolar border
  • Dysplasia of type 2 cells
  • Free alveolar fibrin
  • Cells and debris in alveolar spaces
  • Various stages of interstitial edema, inflammation, and organization

DAD is the histopathologic equivalent of the ARDS.

See the image below.

Histologic section of the lung showing diffuse alv Histologic section of the lung showing diffuse alveolar damage in a patient with adult respiratory distress syndrome.

NSIP

Drug-induced NSIP is a relatively common pulmonary reaction to drugs. The inflammatory process in NSIP is diffuse and uniform, mainly involving the alveolar walls and variably affecting the bronchovascular sheaths and pleura. In drug-induced NSIP, interstitial inflammation is typically more homogeneous and more cellular than that seen in cases of usual interstitial pneumonia. See the image below.

In usual interstitial pneumonitis or idiopathic pu In usual interstitial pneumonitis or idiopathic pulmonary fibrosis, subpleural and paraseptal inflammation is present, with an appearance of temporal heterogeneity. Patchy scarring of the lung parenchyma and normal, or nearly normal, alveoli interspersed between fibrotic areas are the hallmarks of this disease. In addition, the lung architecture is completely destroyed.

COP

Histologically, COP is characterized by variably dense airspace aggregates of loose fibroblasts in ground substance. The lung architecture is typically preserved, and lymphocytes, plasma cells, and histiocytes are present to a variable degree within the interstitium. Nodular organizing pneumonia is typically seen in patients exposed to bleomycin, in the form of round-shaped foci that localize mainly in lung bases, but may abut the pleura and simulate metastatic nodules. See the image below.

Cryptogenic organizing pneumonia (also called bron Cryptogenic organizing pneumonia (also called bronchiolitis obliterans-organizing pneumonia or BOOP) is often patchy and peribronchiolar. The proliferation of granulation tissue within small airways and alveolar ducts is excessive and is associated with chronic inflammation of surrounding alveoli.

Granulomatous pneumonitis

Some drugs are capable of producing a granulomatous inflammation without necrosis. These agents can induce a granulomatous pneumonitis with or without the bronchiolitis and interstitial inflammation seen in hypersensitivity pneumonitis.[60] See the image below.

Close-up view of a noncaseating granuloma with a g Close-up view of a noncaseating granuloma with a giant cell.
Previous
 
 
Contributor Information and Disclosures
Author

Ryland P Byrd, Jr, MD Professor of Medicine, Division of Pulmonary Disease and Critical Care Medicine, James H Quillen College of Medicine, East Tennessee State University

Ryland P Byrd, Jr, MD is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society

Disclosure: Nothing to disclose.

Coauthor(s)

Thomas M Roy, MD Chief, Division of Pulmonary Disease and Critical Care Medicine, Quillen Mountain Home Veterans Affairs Medical Center; Professor of Medicine, Division of Pulmonary Disease and Critical Care Medicine, Fellowship Program Director, James H Quillen College of Medicine, East Tennessee State University

Thomas M Roy, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, Southern Medical Association, Wilderness Medical Society

Disclosure: Nothing to disclose.

Chief Editor

Zab Mosenifar, MD, FACP, FCCP Geri and Richard Brawerman Chair in Pulmonary and Critical Care Medicine, Professor and Executive Vice Chairman, Department of Medicine, Medical Director, Women's Guild Lung Institute, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine

Zab Mosenifar, MD, FACP, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society

Disclosure: Nothing to disclose.

Acknowledgements

Arshad Ali, MD Attending Physician, Department of Pulmonary and Critical Care Medicine, Mercy General Hospital of Sacramento

Arshad Ali, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society

Disclosure: Nothing to disclose. M Frances J Schmidt, MD Chief of Pulmonary Medicine, Pulmonary Fellowship Program, Teaching Attending Physician, Department of Medicine, Interfaith Medical Center

M Frances J Schmidt, MD is a member of the following medical societies: American College of Chest Physicians and American College of Physicians

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Irey NS. Teaching monograph. Tissue reactions to drugs. Am J Pathol. Mar 1976. 82:613-47.

  2. Tamura M, Saraya T, Fujiwara M, Hiraoka S, Yokoyama T, Yano K, et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist. 2013. 18(4):454-9. [Medline]. [Full Text].

  3. Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis. 1993 May. 147(5):1264-70. [Medline].

  4. De Vuyst P, Pfitzenmeyer P, Camus P. Asbestos, ergot drugs and the pleura. Eur Respir J. 1997 Dec. 10(12):2695-8. [Medline].

  5. Hillerdal G, Lee J, Blomkvist A, Rask-Andersen A, Uddenfeldt M, Koyi H, et al. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos. Eur Respir J. 1997 Dec. 10(12):2711-5. [Medline].

  6. Vandenplas O, Hantson P, Dive A, Mahieu P. Fulminant pulmonary edema following intravenous administration of radiocontrast media. Acta Clin Belg. 1990. 45(5):334-9. [Medline].

  7. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J. 1969 Jun 14. 2(5658):651-7. [Medline].

  8. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol. 1969 Nov. 90(5):365-80. [Medline].

  9. Schwarz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med. 2004 Mar. 25(1):133-40. [Medline].

  10. Foucher P, Camus P. Interstitial lung disease. PNEUMOTOX online. Available at http://www.pneumotox.com/indexf.php?fich=clin0&lg=en. Accessed: August 2007.

  11. Drent M, Wijnen P, Bast A. Interstitial lung damage due to cocaine abuse: pathogenesis, pharmacogenomics and therapy. Curr Med Chem. 2012. 19(33):5607-11. [Medline].

  12. Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med. 2010 Sep 15. 182(6):790-6. [Medline]. [Full Text].

  13. Toledo CH, Ross WE, Hood CI, Block ER. Potentiation of bleomycin toxicity by oxygen. Cancer Treat Rep. 1982 Feb. 66(2):359-62. [Medline].

  14. Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur J Cancer. 1996 Mar. 32A(3):550-2. [Medline].

  15. White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer. 1987 May 1. 59(9):1582-5. [Medline].

  16. Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA. Drug-induced pulmonary fibrosis. Saudi Med J. 2004 Jun. 25(6):700-6. [Medline].

  17. Krous HF, Hamlin WB. Pulmonary toxicity due to bleomycin. Report of a case. Arch Pathol. 1973 Jun. 95(6):407-10. [Medline].

  18. Kuhlman JE. The role of chest computed tomography in the diagnosis of drug-related reactions. J Thorac Imaging. 1991 Jan. 6(1):52-61. [Medline].

  19. Balikian JP, Jochelson MS, Bauer KA, Skarkin AT, Garnick MB, Canellos GP, et al. Pulmonary complications of chemotherapy regimens containing bleomycin. AJR Am J Roentgenol. 1982 Sep. 139(3):455-61. [Medline].

  20. Bellamy EA, Husband JE, Blaquiere RM, Law MR. Bleomycin-related lung damage: CT evidence. Radiology. 1985 Jul. 156(1):155-8. [Medline].

  21. Santrach PJ, Askin FB, Wells RJ, Azizkhan RG, Merten DF. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer. 1989 Aug 15. 64(4):806-11. [Medline].

  22. Gehl HB, Hauptmann S, Sohn M, Bohndorf K. [Late pulmonary changes following bleomycin administration in computed tomography. Nodular fibrosis mimicking a seminoma metastasis]. Radiologe. 1992 Feb. 32(2):80-2. [Medline].

  23. White DA, Kris MG, Stover DE. Bronchoalveolar lavage cell populations in bleomycin lung toxicity. Thorax. 1987 Jul. 42(7):551-2. [Medline].

  24. Yousem SA, Lifson JD, Colby TV. Chemotherapy-induced eosinophilic pneumonia. Relation to bleomycin. Chest. 1985 Jul. 88(1):103-6. [Medline].

  25. O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990 Aug 9. 323(6):378-82. [Medline].

  26. Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000. 6(4):387-94. [Medline].

  27. Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). Chest. 1995 Feb. 107(2):482-7. [Medline].

  28. Hamada K, Nagai S, Kitaichi M, Jin G, Shigematsu M, Nagao T, et al. Cyclophosphamide-induced late-onset lung disease. Intern Med. 2003 Jan. 42(1):82-7. [Medline].

  29. Aymard JP, Gyger M, Lavallee R, Legresley LP, Desy M. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung?. Cancer. 1984 Feb 15. 53(4):954-6. [Medline].

  30. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000 Feb. 15(2):373-81. [Medline].

  31. Wollner A, Mohle-Boetani J, Lambert RE, Perruquet JL, Raffin TA, McGuire JL. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax. 1991 Mar. 46(3):205-7. [Medline].

  32. Akoun GM, Mayaud CM, Touboul JL, Denis MF, Milleron BJ, Perrot JY. Use of bronchoalveolar lavage in the evaluation of methotrexate lung disease. Thorax. 1987 Sep. 42(9):652-5. [Medline].

  33. White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis. 1989 Jan. 139(1):18-21. [Medline].

  34. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987 Dec. 14(6):1164-71. [Medline].

  35. Arnon R, Raz I, Chajek-Shaul T, Berkman N, Fields S, Bar-On H. Amiodarone pulmonary toxicity presenting as a solitary lung mass. Chest. 1988 Feb. 93(2):425-7. [Medline].

  36. Piccione W Jr, Faber LP, Rosenberg MS. Amiodarone-induced pulmonary mass. Ann Thorac Surg. 1989 Jun. 47(6):918-9. [Medline].

  37. Sato N, Kojima K, Horio Y, Goto E, Masunaga A, Ichiyasu H, et al. Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion. Chest. 2013 Apr 1. 143(4):1146-50. [Medline].

  38. Greenspon AJ, Kidwell GA, Hurley W, Mannion J. Amiodarone-related postoperative adult respiratory distress syndrome. Circulation. 1991 Nov. 84(5 Suppl):III407-15. [Medline].

  39. Kay GN, Epstein AE, Kirklin JK, Diethelm AG, Graybar G, Plumb VJ. Fatal postoperative amiodarone pulmonary toxicity. Am J Cardiol. 1988 Sep 1. 62(7):490-2. [Medline].

  40. Tuzcu EM, Maloney JD, Sangani BH, Masterson ML, Hocevar KD, Golding LA, et al. Cardiopulmonary effects of chronic amiodarone therapy in the early postoperative course of cardiac surgery patients. Cleve Clin J Med. 1987 Nov-Dec. 54(6):491-7. [Medline].

  41. Gibson GR. Enalapril-induced cough. Arch Intern Med. 1989 Dec. 149(12):2701-3. [Medline].

  42. Kaufman J, Casanova JE, Riendl P, Schlueter DP. Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors. Chest. 1989 Mar. 95(3):544-8. [Medline].

  43. Kaufman J, Schmitt S, Barnard J, Busse W. Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma. Chest. 1992 Apr. 101(4):922-5. [Medline].

  44. Sebastian JL, McKinney WP, Kaufman J, Young MJ. Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population. Chest. 1991 Jan. 99(1):36-9. [Medline].

  45. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004 Feb. 17(2):103-11. [Medline].

  46. Fisman EZ, Grossman E, Motro M, Tenenbaum A. Clinical evidence of dose-dependent interaction between aspirin and angiotensin-converting enzyme inhibitors. J Hum Hypertens. 2002 Jun. 16(6):379-83. [Medline].

  47. Meune C, Mahe I, Mourad JJ, Simoneau G, Knellwolf AL, Bergmann JF, et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review. Eur J Clin Pharmacol. 2000 Dec. 56(9-10):609-20. [Medline].

  48. Tenenbaum A, Grossman E, Shemesh J, Fisman EZ, Nosrati I, Motro M. Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. Am J Hypertens. 2000 Jul. 13(7):776-82. [Medline].

  49. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998 Mar. 18(3):171-88. [Medline].

  50. Meeker DP, Wiedemann HP. Drug-induced bronchospasm. Clin Chest Med. 1990 Mar. 11(1):163-75. [Medline].

  51. Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniack RM. The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. Am Rev Respir Dis. 1986 Feb. 133(2):264-8. [Medline].

  52. Cameron RJ, Kolbe J, Wilsher ML, Lambie N. Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin. Thorax. 2000 Mar. 55(3):249-51. [Medline].

  53. O'Donnell AE, Mappin FG, Sebo TJ, Tazelaar H. Interstitial pneumonitis associated with "crack" cocaine abuse. Chest. 1991 Oct. 100(4):1155-7. [Medline].

  54. Patel RC, Dutta D, Schonfeld SA. Free-base cocaine use associated with bronchiolitis obliterans organizing pneumonia. Ann Intern Med. 1987 Aug. 107(2):186-7. [Medline].

  55. Lassen CL, Zink W, Wiese CH, Graf BM, Wiesenack C. [Naloxone-induced pulmonary edema. Case report with review of the literature and critical evaluation]. Anaesthesist. 2012 Feb. 61(2):129-36. [Medline].

  56. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15. 279(15):1200-5. [Medline].

  57. Rosenow EC 3rd, Limper AH. Drug-induced pulmonary disease. Semin Respir Infect. 1995 Jun. 10(2):86-95. [Medline].

  58. Ohri A, Arena FP. Severe pulmonary complications in African-American patient after bortezomib therapy. Am J Ther. 2006 Nov-Dec. 13(6):553-5. [Medline].

  59. Pietra GG. Pathologic mechanisms of drug-induced lung disorders. J Thorac Imaging. 1991 Jan. 6(1):1-7. [Medline].

  60. Kornacker M, Kraemer A, Leo E, Ho AD. Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases. Ann Hematol. 2002 Feb. 81(2):103-5. [Medline].

  61. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant. 2012 Oct. 31(10):1073-86. [Medline].

 
Previous
Next
 
Standard nonenhanced axial thoracic CT scan shows left lower lobe consolidation with some loss of volume and an air bronchogram. Transbronchial lung biopsy confirmed the diagnosis of cryptogenic organizing pneumonia.
CT scan of a patient with sarcoidosis illustrating multiple nodules. This pattern can manifest in patients taking medications that can cause granulomatous reactions.
Histologic section of the lung showing diffuse alveolar damage in a patient with adult respiratory distress syndrome.
In usual interstitial pneumonitis or idiopathic pulmonary fibrosis, subpleural and paraseptal inflammation is present, with an appearance of temporal heterogeneity. Patchy scarring of the lung parenchyma and normal, or nearly normal, alveoli interspersed between fibrotic areas are the hallmarks of this disease. In addition, the lung architecture is completely destroyed.
Cryptogenic organizing pneumonia (also called bronchiolitis obliterans-organizing pneumonia or BOOP) is often patchy and peribronchiolar. The proliferation of granulation tissue within small airways and alveolar ducts is excessive and is associated with chronic inflammation of surrounding alveoli.
Lung biopsy specimen from the patient with sarcoidosis (see CT scan illustrating multiple nodules). Multiple areas of noncaseating granulomas are present. Drugs such as methotrexate, nitrofurantoin, procarbazine, and pentazocine can cause granulomatous lung disease.
Close-up view of a noncaseating granuloma with a giant cell.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.